Overview

Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether the Tacrolimus added to histidine-tryptophan-ketoglutarate (HTK) solution given through intraportal and intraarterial infusion during back-table procedure is capable of reducing the degree of early allograft liver dysfunction, as assessed by postoperative levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), during first 7 postoperative days and by serum and histochemical markers of liver injury and inflammation.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Republican Scientific and Practical Center for Organ and Tissue Transplantation
Treatments:
Tacrolimus
Criteria
Inclusion Criteria:

- Donor:

age 15-65 years macrovesicular steatosis < 40% (macroscopy or biopsy) sodium <165 mmol/l
ICU stay and ventilation < 11 days cold ischemia time < 13 hours AST < 200 U/l ALT < 200
U/l bilirubin < 50 μmol/l application of norepinephrine is allowed

- Recipient age: 18-69

Exclusion Criteria:

Recipient:

- live donor liver transplant

- reduced and split grafts

- multi organ failure